Barrier Therapeutics is a biopharmaceutical company founded in 2002 with a focus on developing and commercializing innovative pharmaceutical products in the field of dermatology. The company is dedicated to addressing significant medical needs within the dermatological space. With a strong emphasis on clinical development, Barrier Therapeutics has multiple product candidates based on licensed intellectual property from third parties, with four candidates in or nearing Phase III clinical trials.
The company operates within the biopharma, healthcare, and health and wellness industries, positioning itself at the intersection of innovation and crucial medical requirements. While specific details about the headquarters and last investment are unavailable, Barrier Therapeutics is actively advancing its pipeline, potentially attracting the interest of investors seeking opportunities in the biopharmaceutical sector.
There is no investment information
No recent news or press coverage available for Barrier Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
